Acta Scientific Clinical Case Reports

Case Report Volume 1 Issue 9

Single-Agent Weekly Carboplatin for Disseminated Carcinomatosis of Bone Marrow Arising from Breast Cancer. A Case-Report

Boris Itkin1, Lucía Kaminszczik1*, María Belén Centurión2 and Sebastián Lescano3

1Department of Clinical Oncology, Juan A Fernández Hospital, Buenos Aires, Argentina
2Department of Pathology, Juan A Fernández Hospital, Buenos Aires, Argentina
3Department of Medical Imaging, Juan A Fernández Hospital, Buenos Aires, Argentina

*Corresponding Author: Lucía Kaminszczik, Department of Clinical Oncology, Juan A Fernandez Hospital, Buenos Aires, Argentina.

Received: July 13, 2020; Published: August 19, 2020

×

Abstract

Disseminated bone marrow carcinomatosis (DBMC) is an infrequent manifestation of advanced breast cancer which can be accompanied by life-threatening clinical complications. The optimal management of the condition is unknown due to the paucity of published studies. We report a case of young female patient with DBMC as a part of the systemic relapse of hormone receptor positive, HER2 negative breast cancer. At the onset of DBMC, due to severe thrombocytopenia (18,000/mm3) and clinical deterioration, she required hospitalization and platelets transfusions. Her Eastern Cooperative Oncology Group Performance Status was 3. After doxorubicin failure, considering her familial history of multiple relatives with breast cancer, single-agent weekly carboplatin has been started at the dose AUC 2 with gradual normalization of the marrow function, important clinical amelioration and without significant toxicity. The survival time from DBMC diagnosis was 11 months. BRCA testing was not performed. In some very carefully selected patients with DBMC, single-agent weekly carboplatin may be considered as a treatment option.

Keywords: Bone Marrow Carcinomatosis; Disseminated Carcinomatosis of Bone Marrow; Breast Cancer; Carboplatin; Thrombocytopenia

×

References

  1. Shinden Yoshiaki., et al. "Clinicopathological Characteristics of Disseminated Carcinomatosis of the Bone Marrow in Breast Cancer Patients”. Molecular and Clinical Oncology 8.1 (2018): 93-98.
  2. Xiao L., et al. "Diagnosis of Unknown Nonhematological Tumors by Bone Marrow Biopsy: A Retrospective Analysis of 10,112 Samples”. Journal of Cancer Research and Clinical Oncology 135.5 (2009): 687-693.
  3. Kopp HG., et al. "Symptomatic Bone Marrow Involvement in Breast Cancer--Clinical Presentation, Treatment, and Prognosis: A Single Institution Review of 22 Cases”. Anticancer Research 31.11 (2011): 4025-4030.
  4. Demir L., et al. "Prognostic Evaluation of Breast Cancer Patients with Evident Bone Marrow Metastasis”. Breast Journal 20.3 (2014): 279-87.
  5. Kawai H., et al. "A Case of Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation Arising from Breast Cancer Successfully Treated with Paclitaxel Plus Bevacizumab”. Gan To Kagaku Ryoho 41.12 (2014): 1957-1979.
  6. Takayama S., et al. "A Case of Bone Marrow Carcinomatosis from Breast Cancer Treated with Weekly Paclitaxel”. Gan To Kagaku Ryoho 39.1 (2012): 99-101.
  7. Iguchi H. "Recent Aspects for Disseminated Carcinomatosis of the Bone Marrow Associated with Gastric Cancer: What Has Been Done for the Past, and What Will Be Needed in Future?" World Journal of Gastroenterology 21.43 (2015): 12249-12260.
  8. Ota T., et al. "Use of Hormone Therapies in Disseminated Carcinomatosis of the Bone Marrow Associated with Hormone Receptor-Positive Breast Cancer”. Gynecology Endocrinology 34.4 (2018): 286-289.
  9. Nakayama I. "Clinical Efficacy of Paclitaxel Plus Bevacizumab Combination Therapy for Bone Marrow Carcinomatosis Arising from Breast Cancer - a Case Report”. Gan To Kagaku Ryoho 44.12 (2017): 1391-1392.
  10. Robson M., et al. "Protocol. Olaparib for Metastatic Breast Cancer in Patients with a Germline Brca Mutation”. 
  11. Raez Luis E and Edgardo S Santos. "Tumor Type-Agnostic Treatment and the Future of Cancer Therapy”. Targeted Oncology 13 (2018): 541-544.
  12. Caramelo O., et al. "The Effect of Neoadjuvant Platinum-Based Chemotherapy in Brca Mutated Triple Negative Breast Cancers -Systematic Review and Meta-Analysis”. Hereditary Cancer in Clinical Practice 17 (2019): 11.
  13. Hahnen Eric., et al. "Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the Geparsixto Randomized Clinical Trial”. JAMA Oncology 3 (2017): 1378-85.
  14. Kamata A., et al. "A Case of Disseminated Bone Marrow Carcinomatosis Arising from Breast Cancer for Which Paclitaxel and Bevacizumab Treatment Was Effective”. Gan To Kagaku Ryoho 43.1 (2016): 103-106.
×

Citation

Citation: Lucía Kaminszczik., et al. “Single-Agent Weekly Carboplatin for Disseminated Carcinomatosis of Bone Marrow Arising from Breast Cancer. A Case-Report”. Acta Scientific Clinical Case Reports 1.9 (2020): 08-12.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.278

Indexed In





News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 25, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US